These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24573384)

  • 21. [Expression of miR-16 in patients with T lymphoblastic lymphoma/acute lymphoblastic leukemia].
    Tong LG; Wu WZ; Zhang YP; Zhou ZG; Chen YF; Huang WJ; Xu H; Su QQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):99-103. PubMed ID: 24598659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new hope for early T cell precursor acute lymphoblastic leukemia therapy based on STAT5+ leukemic stem cell targeting.
    Pelayo R
    J Leukoc Biol; 2023 Oct; 114(5):381-383. PubMed ID: 37607260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways.
    Bonaccorso P; Bugarin C; Buracchi C; Fazio G; Biondi A; Lo Nigro L; Gaipa G
    Cytometry B Clin Cytom; 2020 Nov; 98(6):491-503. PubMed ID: 32479694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunophenotyping with CD135 and CD117 predicts the FLT3, IL-7R and TLX3 gene mutations in childhood T-cell acute leukemia.
    Noronha EP; Andrade FG; Zampier C; de Andrade CF; Terra-Granado E; Pombo-de-Oliveira MS;
    Blood Cells Mol Dis; 2016 Mar; 57():74-80. PubMed ID: 26852660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Stat5b transgene is capable of inducing CD8+ lymphoblastic lymphoma in the absence of normal TCR/MHC signaling.
    Bessette K; Lang ML; Fava RA; Grundy M; Heinen J; Horne L; Spolski R; Al-Shami A; Morse HC; Leonard WJ; Kelly JA
    Blood; 2008 Jan; 111(1):344-50. PubMed ID: 17890450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
    Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
    Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
    Diamanti P; Ede BC; Dace PE; Barendt WJ; Cox CV; Hancock JP; Moppett JP; Blair A
    Br J Haematol; 2021 Feb; 192(3):577-588. PubMed ID: 32452017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New genetic abnormalities and treatment response in acute lymphoblastic leukemia.
    Meijerink JP; den Boer ML; Pieters R
    Semin Hematol; 2009 Jan; 46(1):16-23. PubMed ID: 19100364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Signal Transducer and Activator of Transcription 5B (STAT5B) Gene Promotes Proliferation and Drug Resistance of Human Mantle Cell Lymphoma Cells by Activating the Akt Signaling Pathway.
    Zhang W; Liang X; Gong Y; Xiao C; Guo B; Yang T
    Med Sci Monit; 2019 Apr; 25():2599-2608. PubMed ID: 30964854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
    Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
    Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia.
    Sanchez-Martin M; Ferrando A
    Blood; 2017 Mar; 129(9):1124-1133. PubMed ID: 28115368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
    Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
    Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines.
    Anderson NM; Harrold I; Mansour MR; Sanda T; McKeown M; Nagykary N; Bradner JE; Lan Zhang G; Look AT; Feng H
    Leukemia; 2014 May; 28(5):1145-8. PubMed ID: 24342948
    [No Abstract]   [Full Text] [Related]  

  • 34. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.
    Trinquand A; Tanguy-Schmidt A; Ben Abdelali R; Lambert J; Beldjord K; Lengliné E; De Gunzburg N; Payet-Bornet D; Lhermitte L; Mossafa H; Lhéritier V; Bond J; Huguet F; Buzyn A; Leguay T; Cahn JY; Thomas X; Chalandon Y; Delannoy A; Bonmati C; Maury S; Nadel B; Macintyre E; Ifrah N; Dombret H; Asnafi V
    J Clin Oncol; 2013 Dec; 31(34):4333-42. PubMed ID: 24166518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia.
    Heltemes-Harris LM; Willette MJ; Ramsey LB; Qiu YH; Neeley ES; Zhang N; Thomas DA; Koeuth T; Baechler EC; Kornblau SM; Farrar MA
    J Exp Med; 2011 Jun; 208(6):1135-49. PubMed ID: 21606506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols.
    Zuurbier L; Homminga I; Calvert V; te Winkel ML; Buijs-Gladdines JG; Kooi C; Smits WK; Sonneveld E; Veerman AJ; Kamps WA; Horstmann M; Petricoin EF; Pieters R; Meijerink JP
    Leukemia; 2010 Dec; 24(12):2014-22. PubMed ID: 20861909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia.
    Grossmann V; Kern W; Harbich S; Alpermann T; Jeromin S; Schnittger S; Haferlach C; Haferlach T; Kohlmann A
    Haematologica; 2011 Dec; 96(12):1874-7. PubMed ID: 21828118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Restricted STAT5 activation dictates appropriate thymic B versus T cell lineage commitment.
    Goetz CA; Harmon IR; O'Neil JJ; Burchill MA; Johanns TM; Farrar MA
    J Immunol; 2005 Jun; 174(12):7753-63. PubMed ID: 15944278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations.
    Rajala HL; Porkka K; Maciejewski JP; Loughran TP; Mustjoki S
    Ann Med; 2014 May; 46(3):114-22. PubMed ID: 24512550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
    Papayannidis C; DeAngelo DJ; Stock W; Huang B; Shaik MN; Cesari R; Zheng X; Reynolds JM; English PA; Ozeck M; Aster JC; Kuo F; Huang D; Lira PD; McLachlan KR; Kern KA; Garcia-Manero G; Martinelli G
    Blood Cancer J; 2015 Sep; 5(9):e350. PubMed ID: 26407235
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.